These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29099947)

  • 1. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.
    Vokes TJ; Mannstadt M; Levine MA; Clarke BL; Lakatos P; Chen K; Piccolo R; Krasner A; Shoback DM; Bilezikian JP
    J Clin Endocrinol Metab; 2018 Feb; 103(2):722-731. PubMed ID: 29099947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
    Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
    Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.
    Tabacco G; Tay YD; Cusano NE; Williams J; Omeragic B; Majeed R; Almonte MG; Rubin MR; Bilezikian JP
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2748-2756. PubMed ID: 30776291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.
    Bilezikian JP; Clarke BL; Mannstadt M; Rothman J; Vokes T; Lee HM; Krasner A
    Clin Ther; 2017 Oct; 39(10):2096-2102. PubMed ID: 28942334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
    Lakatos P; Bajnok L; Lagast H; Valkusz Z
    Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.
    Palermo A; Santonati A; Tabacco G; Bosco D; Spada A; Pedone C; Raggiunti B; Doris T; Maggi D; Grimaldi F; Manfrini S; Vescini F
    J Clin Endocrinol Metab; 2018 Jan; 103(1):271-280. PubMed ID: 29099939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
    Gittoes N; Rejnmark L; Ing SW; Brandi ML; Björnsdottir S; Hahner S; Hofbauer LC; Houillier P; Khan AA; Levine MA; Mannstadt M; Shoback DM; Vokes TJ; Zhang P; Marelli C; Germak J; Clarke BL
    BMC Endocr Disord; 2021 Nov; 21(1):232. PubMed ID: 34801015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
    Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
    Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
    J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
    Khan AA; Rejnmark L; Rubin M; Schwarz P; Vokes T; Clarke B; Ahmed I; Hofbauer L; Marcocci C; Pagotto U; Palermo A; Eriksen E; Brod M; Markova D; Smith A; Pihl S; Mourya S; Karpf DB; Shu AD
    J Clin Endocrinol Metab; 2022 Jan; 107(1):e372-e385. PubMed ID: 34347093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.
    Santonati A; Palermo A; Maddaloni E; Bosco D; Spada A; Grimaldi F; Raggiunti B; Volpe R; Manfrini S; Vescini F;
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3590-7. PubMed ID: 26196949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
    Tay YD; Tabacco G; Cusano NE; Williams J; Omeragic B; Majeed R; Gomez Almonte M; Bilezikian JP; Rubin MR
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5601-5610. PubMed ID: 31310310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
    Rejnmark L; Gosmanova EO; Khan AA; Makita N; Imanishi Y; Takeuchi Y; Sprague S; Shoback DM; Kohlmeier L; Rubin MR; Palermo A; Schwarz P; Gagnon C; Tsourdi E; Zhao C; Makara MA; Ominsky MS; Lai B; Ukena J; Sibley CT; Shu AD
    Adv Ther; 2024 Jun; 41(6):2500-2518. PubMed ID: 38691316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
    Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
    Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
    Marcucci G; Della Pepa G; Brandi ML
    Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
    Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
    Kim ES; Keating GM
    Drugs; 2015 Jul; 75(11):1293-303. PubMed ID: 26177893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid Hormone Replacement Therapy in Hypoparathyroidism: A Meta-Analysis.
    Liu XX; Zhu XY; Mei GH
    Horm Metab Res; 2016 Jun; 48(6):377-83. PubMed ID: 27254756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.